Patrick Eimerman

Company: Saga Diagnostics AB

Job title: Vice President - Business Development and Partnerships

Seminars:

Next-Gen MRD: Increasing Access to Ultrasensitive ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs 2:30 pm

The Pathlight MRD test is an ultrasensitive, cost-effective approach to MRD detection and quantification to <1 PPM using WGS proprietary dPCR methods to track structural variants Structural Variants (SVs) are highly prevalent across indications and are an ideal pancancer biomarker for determining MRD status Clinical studies in breast and ovarian cancers demonstrate improved detection of…Read more

day: Conference Day 1